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Background. In this study we investigated the relevance of myostatin and Hepatocyte Growth Factor (HGF) in patients undergoing
hemodialysis HD and the influence of differentHDmodalities on their levels.Methods.Weperformed a prospective crossover study
in which HD patients were randomized to undergo 3-month treatment periods with bicarbonate hemodialysis (BHD) followed by
online hemodiafiltration (HDF). Clinical data, laboratory parameters, and myostatin and HGF serum levels were collected and
compared. Results. Ten patients and six controls (C) were evaluated. In any experimental condition myostatin and HGF levels
were higher in HD than in C. At enrollment and after BHD there were not significant correlations, whereas at the end of the HDF
treatment periodmyostatin andHGFwere inversely correlated (! −0.65,# < 0.05),myostatin serum levels inversely correlatedwith
transferrin (! − 0.73, # < 0.05), and HGF levels that resulted positively correlated with BMI (! 0.67, # < 0.05). Moving from BHD
toHDF, clinical and laboratory parameters were unchanged, as well as serumHGF, whereasmyostatin levels significantly decreased
(6.3 ± 4.1 versus 4.3 ± 3.1 ng/ml, # < 0.05). Conclusions.Modulation of myostatin levels and myostatin/HGF balance by the use of
differentHDmodalitiesmight represent a novel approach to the prevention and treatment ofHD-relatedmuscle wasting syndrome.
1. Introduction
Patients suffering from chronic kidney disease (CKD),
mainly those undergoing hemodialysis (HD), often present
malnutrition and muscle wasting syndrome, which directly
correlate with morbidity and mortality [1]. Several mecha-
nisms have been involved in the regulation of energy and
muscular homeostasis, including cytokines and molecules
with systemic and paracrine action (the so-called “myoki-
nes”) and intracellular signalling pathways, that may have
positive or negative effects on muscle growth, also affecting
muscle response to injury through the inhibition or stimu-
lation of muscle stem cells (“satellite cells”) [2]. The Growth
Differentiation Factor-8 (GDF-8)/myostatin, a member of
TGF-$ family, is primarily expressed in skeletal muscle and
has the effect of limiting muscle growth. It also circulates
in the blood and acts on muscle tissue, binding a cell-
bound receptor called Activin type 2B [3].The importance of
myostatin was emphasized by several studies, demonstrating
its increase in muscular atrophy and chronic disease [4–6].
The Hepatocyte Growth Factor (HGF) is another key fac-
tor in the regulation of skeletal muscle homeostasis. HGFwas
firstly recognized as a product of mesenchymal cells with an
action predominantly addressed to stimulate growth, motil-
ity, and differentiation of epithelial-derived cells [7]. Subse-
quently, it has been demonstrated that HGF is also present in
muscle tissue and is essential for the response to cellular dam-
age and the repair of damaged tissue, inducing activation and
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rapid cell division ofmuscle satellite cells [8]. In CKDpatients
an upregulation of myostatin gene expression in skeletal
muscle has been found, which was strictly related to IL-6
expression, suggesting a link betweenmyostatin andmicroin-
flammation [9]. Moreover, it has been demonstrated in the
clinical setting thatmyostatin serum levels inHD patients are
elevated and inversely related to muscle strength [10].
Similarly, also HGF levels appear to be influenced by
uremia and HD. Indeed, it has been proved that HD causes
a prompt and prolonged release of HGF into the circulation,
mainly because of the leukocyte activation associated with
HD treatment [11].
Therefore, considering their elevated circulating levels
and apparently opposite effects onmuscular metabolism, it is
conceivable that myostatin andHGF accumulation, as well as
their balance, may be important in the pathogenesis of mal-
nutrition and muscle wasting syndrome in uremic subjects.
This is the reason why we decided to investigate the
relevance of myostatin and HGF in HD patients and whether
their serum levels could be modulated by using different HD
modalities.
2. Patients and Methods
We performed a prospective 6-month crossover study,
enrolling clinically stable uremic patients undergoing stan-
dard bicarbonate hemodialysis (BHD) at least for 6 months.
Patients with acute infections, active immunological diseases,
immunosuppressive therapy, previous transplantation, or
history of malignancies were excluded from the study. Sex-
matched healthy subjects were the control group. Patients
were randomized into two groups according to a 2 × 2
crossover design. Group 1was treated with BHD for the first 3
months and then switched to online hemodiafiltration (HDF)
for additional 3 months; group 2 was initially treated with
HDF and then with BHD.
BHD was performed with cellulose diacetate membranes
(DICEA, Baxter Healthcare, Baxter, Iowa, USA) with a blood
flow of 300–350ml/min and a dialysate flow of 600ml/min.
InHDF, the replacement volumewas standardized to 25–30%
of the total treated blood volume, using a high-flux Helixone
membrane (FX100, Fresenius Medical Care, Bad Homburg,
Germany).
At the beginning of the study (enrollment phase) and at
the end of each experimental period we evaluated anthro-
pometric and nutritional parameters, including body mass
index (BMI), predialysis serum levels of phosphate, albumin,
transferrin, lymphocyte count, and blood urea nitrogen, and
dialysis adequacy (evaluated as single pool KT/V-spKT/V).
In each patient, before the hemodialysis session, serum was
withdrawn and tested for HGF and myostatin levels by
ELISA (Quantikine; R&D Systems, Minneapolis, MN, USA;
detection limit 40 pg/ml and 5.3 pg/ml, resp.), assuming those
samples presenting values under the detection limit as zero.
The study was conducted in accordance with the Declara-
tion of Helsinki and was approved by the Ethics Committee
of the Fondazione IRCCS Policlinico San Matteo of Pavia,
Italy. Written informed consent was obtained from each
participant prior to enrollment in the study.
2.1. Statistical Analysis. Quantitative variables were repre-
sented by mean ± standard deviation (SD) or interquartile
ranges (IQR) if they were not normally distributed (Shapiro
Test).
Differences among control subjects and HD patients in
different experimental conditions were assessed by analysis
of variance (ANOVA), Student’s &-test, or nonparametric
Mann–Whitney test when appropriated. In order to evaluate
a possible carry-over effect, we compared the variations of
myostatin and HGF levels between subjects of group 1 (i.e.,
starting with BHD) versus group 2 (i.e., starting with HDF).
Correlations among myostatin, HGF levels, and variables
were analyzed with Spearman-Rho. All tests were two-sided
and # < 0.05 was considered statistically significant. Data
analysis was performed with GraphPad Prism statistical
package (version 5.00, GraphPad Software, San Diego, Cal-
ifornia, USA).
3. Results
3.1. Patient Characteristics. We enrolled ten patients (65.5 ±13.1 years, seven males) with a dialysis vintage of 70.8 ± 18
months.
Mean BMI was 28.4 ± 4.7 kg/m2; three patients were dia-
betic. At the time of enrollment all patients were undergoing
thrice-weekly 4-hour BHD, with spKT/V of 1.46 ± 0.4.
Six healthy subjects (48.1 ± 12.7 years, four males; BMI26.5 ± 2.3 kg/m2, # = 0.3 versus patients) constituted
the control group (C). After randomization, five patients
(50%) underwent BHD as initial treatment (group 1) and five
received HDF (group 2).
3.2. Myokine Profile. At enrollment and during the two
different experimental conditions (BHD or HDF) myostatin
levels in patients resulted higher than in C, without reaching
statistical significance (at enrollment 6 ± 3.4 versus 3.1 ±0.6 ng/ml, resp., # = 0.07).
On the opposite, HGF resulted under the detection limit
inC and fourHDpatients, reaching levels of 150.5 pg/ml (IQR
44.2–681) in the remaining six HD patients.
The correlation analysis performed on data collected at
each experimental phase showed that, at enrollment and the
end of BHD period, myostatin levels did not correlate with
any clinical (age, dialytic vintage, and BMI) and laboratory
(albumin, transferrin, phosphorus, and calcium) parameter.
On the contrary,myostatin levelsmeasured at the end ofHDF
period resulted in being inversely correlated with transferrin
(! = −0.73, # < 0.05) and HGF levels (! = −0.65, # < 0.05).
Interestingly, similar results were obtained forHGF levels.
Indeed, while HGF did not correlate with any variable at
the enrollment and after BHD, it resulted in being positively
correlated with BMI (! = 0.67, # < 0.05) at the end of HDF
treatment.
3.3. Effect of Different Dialytic Treatments. During the two
different treatment periods, there were no significant changes
in clinical and laboratory parameters (Table 1).
After shifting from BHD to HDF, HGF levels remained
unchanged [BHD 93 (IQR 42–231.8) versus HDF 156.7 (IQR
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Table 1: Laboratory and dialysis parameters in patients at enrollment and at the end of each treatment periodwith different dialysismodalities.
Enrollment BHD HDF #
BMI (kg/m2) 28.4 ± 4.7 28.8 ± 4.8 28.9 ± 5.1 0.5
Serum albumin (g/dl) 3.8 ± 0.3 3.7 ± 0.2 3.8 ± 0.2 0.5
C-RP (mg/dl) 0.47 (9.3–0.67) 0.6 (0.3–1) 0.45 (0.3–0.77) 0.3
Transferrin (mg/dl) 157.8 ± 15.1 167.7 ± 42.3 172.2 ± 32.1 0.2
Phosphate (mg/dl) 4.4 (3.8–5.7) 4.7 (4.3–5.3) 4.1 (3.9–4.7) 0.5
Calcium (mg/dl) 9 ± 0.3 9.3 ± 0.6 9.2 ± 0.5 0.6
PTH (pg/ml) 210 (149–359) 173.9 (106–599) 227 (156–361) 0.3
Lymphocyte count 1283 ± 673 1255 ± 588 1396 ± 567 0.5
BUN (mg/dl) 71.4 ± 8.6 80.2 ± 18.5 77.2 ± 13.1 0.4
spKT/V 1.46 ± 0.4 1.36 ± 0.25 1.42 ± 0.2 0.4
Predialysis myostatin (ng/ml) 6.0 ± 3.4 6.3 ± 4.1 4.3 ± 3.1 0.001∗
Number of patients 10 10 10
Predialysis HGF (pg/ml) 150.5 (44.2–681) 93 (42–231.8) 156.7 (88–201) 0.2
Number of patients 6 6 7
Data are expressed as mean SD or IQR (25–75).
BHD = bicarbonate hemodialysis; HDF = online hemodiafiltration; C-RP = C-reactive protein; BUN = blood urea nitrogen; spKT/V = single-pool KT/V; HGF





















Figure 1: Effect of different dialysis modalities on myostatin serum
levels. BHD = bicarbonate hemodialysis; HDF = online hemodiafil-
tration. At the enrollment all the patients were on BDH for at least 6
months. ∗# < 0.05 versus enrollment and BHD.
88–201) pg/ml, # = 0.2], whereas serum myostatin levels
significantly decreased [BHD 6.3 ± 4.1 versus HDF 4.3 ±3.1 ng/ml, # = 0.001 (Figure 1)].The differences in myostatin
levels from BHD to HDF were −1.4 ± 1.7 ng/ml for group 1
and −1.1 ± 2.3 ng/ml for group 2, # = 0.9.
Therefore, starting with BHD or HDF did not seem to
have a significant impact on HD modality-induced changes
in myostatin levels.
4. Discussion
With this study we have demonstrated that in regular HD
patients the use of different HD modalities could have dif-
ferent effects on myokine balance. In particular online HDF,
a convective dialytic technique associated with better depu-
ration capacity and a higher rate of cytokine removal, signif-
icantly reduced myostatin levels, without affecting HGF [12].
This is an important consideration since myostatin and
HGF seem to exert opposite effects on the modulation of
muscle cell metabolism. In fact, myostatin, where serum
levels are elevated in CKD and in cachectic states, may act
as a negative regulator of muscle growth and differentiation
[13, 14], whereas HGF exerts proliferative and differentiative
stimuli on muscle cells. So, it is possible that these molecules
play a role in the pathogenesis of muscle wasting in HD, also
by a feedbackmechanism. However, our findings highlighted
that only in patients undergoing online HDF myostatin and
HGF resulted in being inversely correlated. Similarly, we
found that only during HDF myostatin and HGF revealed
a relationship with nutritional parameters. In particular,
myostatin, as expected by its role as negative metabolic
regulator, was inversely related to transferrin, a parameter
strongly associated with a good nutritional status [15]. On the
opposite, HGF was directly related to BMI, which, in turn,
seems to be protective in HD patients [16].
Therefore, it seems that high-volume online HDF treat-
ment could be able to restore a more “physiological” condi-
tion in which myostatin and HGF are counterregulated and
correlated with nutritional parameters.
This preliminary finding, which surely needs further
confirmations, together with the evidence that BHD and
HDF exert different effects on myostatin and HGF levels,
might have a great clinical relevance. Indeed, in the past years
research activity has been addressed to the development of
new dialysis modalities, mainly convective techniques, which
could improve clearance of uremic toxins, also providing
higher clearances of middle molecules, such as inflammatory
cytokines [17].
In this view, high-volume online HDF, using high bio-
compatible membranes and ultrapure dialysate, has been
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found to be more efficient than standard BHD, resulting in
being also associated with a lower mortality rate [18–20]. Our
data provide new and intriguing evidence on the potential
advantages of convective strategies, showing that the use of
HDF, through the modulation of myokine levels, might also
promote a state of better muscle trophism, as previously only
hypothesized [21]. This is particularly relevant considering
that, in spite of several efforts to understand the underlying
mechanisms of these high-risk conditions, currently there are
no established strategies to prevent andmanage malnutrition
and wasting syndrome in HD.
On the other hand, there is a growing interest in the
study of myokines, in particular myostatin, as therapeutic
targets for the treatment of skeletal muscle wasting/atrophy
under diverse clinical settings, including denervation, AIDS,
cancer, diabetes, and chronic heart failure [22]. Indeed, sev-
eral experimental studies demonstrated that pharmacological
inhibition of myostatin by genetic interference or specifically
designed antibody was associated with increased muscle
mass and improved metabolic profile [23, 24], suggesting
that myokine modulation might realistically represent a
promising approach to prevent and treat muscle wasting.
We are aware that our data present some weaknesses. In
fact, although the crossover design of our study was intended
to reduce interindividual heterogeneity, since each patient
served as his own control, the small number of patients
enrolled constitutes a limitation of this study.
Moreover, we did not perform a structured assessment of
the nutritional status of our patients, also considering that the
treatment periods were probably too short to appreciate any
significant clinical change in muscle mass or strength.
5. Conclusions
Malnutrition andmuscle wasting syndrome remain unsolved
problems in HD patients, strictly related to the elevated mor-
bidity and mortality distinctive of this patient population.
Therefore, the understanding of underlying mechanisms
could provide new therapeutic targets and strategies to face
these conditions. With the preliminary findings of our study
we offer a new point of view on this issue, showing that the
use of differentHDmodalities, in particular convective-based
techniques, can influence myokine profile.
In light of this evidence, we hypothesize that HD-
mediated myokine modulation might potentially represent
a novel approach to the prevention and treatment of HD-
related muscle wasting syndrome. Prospective studies with a
larger number of patients are needed to confirm these data
and evaluate their clinical impact.
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